Temazepam (Euhypnos) as a hypnotic: a twelve-week trial in general practice

Area of Science:

• Pharmacology
• Sleep Medicine
• Clinical Therapeutics

Background:

• Insomnia is a prevalent sleep disorder affecting a significant portion of the population.
• Effective and safe hypnotic medications are crucial for managing insomnia.
• Temazepam has been utilized as a hypnotic agent, but its real-world performance and safety profile warrant continued investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of soft gelatine capsules containing temazepam (Euhypnos) in patients requiring hypnotic treatment.
• To assess the hypnotic performance and hangover effects associated with temazepam use.
• To determine the incidence of adverse reactions and drug-related accidents during a 12-week treatment period.

Main Methods:

• A study involving 147 patients requiring hypnotic medication.
• Patients received soft gelatine capsules of temazepam (Euhypnos) at doses of 10-30 mg nightly for up to 12 weeks.
• Assessment of hypnotic performance, hangover effects, adverse reactions, and impact on work performance.

Main Results:

• 90.5% of 133 patients completed the 12-week treatment.
• Hypnotic performance was rated Good or Very Good in 90% of assessments.
• 93.2% of assessments reported no hangover effect, and 96.6% noted no adverse effect on work.
• Occasional headaches and nausea were reported as adverse reactions; no drug-related accidents occurred.

Conclusions:

• Soft gelatine capsules of temazepam (Euhypnos) are an effective and well-tolerated hypnotic for short-term use.
• The medication demonstrates a favorable safety profile with minimal adverse effects and no significant impact on daily functioning.
• Patients who discontinued treatment early often resumed normal sleep patterns without further need for hypnotics.